Fingolimod Hydrochloride

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C72782

162359-56-0

CHEBI:63112

C19H33NO2.HCl

C72782

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

FDA

The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively targets and binds to S1PR1 on lymphocytes and causes transient receptor activation followed by S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory M2 phenotype, and modulates their proliferation, morphology, and cytokine release via inhibition of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7).

Fingolimod Hydrochloride

G926EC510T

2-Amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol Hydrochloride

FTY720

Gilenya

FTY-720

Fingolimod Hydrochloride

FINGOLIMOD HYDROCHLORIDE

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C74202

Fingolimod Hydrochloride

Fingolimod_Hydrochloride

Fingolimod Hydrochloride

Thesaurus:C72782

Fingolimod Hydrochloride

Pharmacologic Substance

C0388087

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C308